Indications for Intravenous Iron Therapy in Advanced Chronic Kidney Disease

Why Oral Iron Is Inadequate

Assessment of Iron Deficiency Prior to IV Therapy

Iron Repletion Targets and Discontinuation

Monitoring and Follow‑Up

Safety Considerations

When to Initiate ESA Therapy

Common Pitfalls to Avoid

Iron Supplementation Guidelines for Elderly CKD Patients

Introduction to Iron Deficiency in CKD

• The American College of Cardiology recommends that elderly CKD patients with iron deficiency be treated immediately, as iron deficiency is defined by low iron saturation and low-normal ferritin levels, with a target iron saturation of ≥20% and ferritin ≥100 ng/mL for non-dialysis CKD patients 6

Route of Administration: IV vs Oral Iron

• The European Society of Cardiology suggests that for elderly non-dialysis CKD patients, either IV or oral iron is acceptable, though IV iron is preferred when feasible, with a dosing regimen of 500 mg IV initially, followed by 500 mg IV 4 weeks later 6, 7
• IV iron has advantages, including bypassing hepcidin-mediated intestinal absorption block, and achieves hemoglobin increases of 7-10 g/L compared to only 4-7 g/L with oral iron, with a response rate of 59.4% of non-dialysis CKD patients responding to IV iron alone without requiring ESA therapy 7, 8
• Oral iron dosing is 200 mg elemental iron daily for 1-3 months, but has limitations in elderly patients, including gastrointestinal side effects, and the European Heart Journal recommends using low-dose oral iron therapy in vulnerable elderly to minimize these side effects 6, 9, 10

Target Iron Parameters During Treatment

• The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends maintaining ferritin ≥100 ng/mL and TSAT ≥20% throughout treatment, with ideal targets of ferritin 400-600 ng/mL and TSAT ≥30% for optimal hemoglobin response 6, 8
• Iron supplementation should be stopped when ferritin exceeds 500-800 ng/mL or TSAT exceeds 50% 6, 9

Monitoring Schedule

• The American Society of Nephrology recommends checking hemoglobin 2-4 weeks after completing iron course, and waiting at least 4 weeks before rechecking ferritin and TSAT after IV iron, as both become falsely elevated immediately post-infusion 8, 9
• TSAT and ferritin should be checked every 3 months once treatment is established, and hemoglobin should be monitored every 3 months for CKD stage 4-5 patients 6, 9

Critical Pitfalls to Avoid in Elderly CKD Patients

• The European Heart Journal warns against assuming normal ferritin means adequate iron, as ferritin can be falsely elevated by inflammation, and recommends monitoring iron status to avoid iron overload, stopping supplementation when ferritin exceeds 500-800 ng/mL or TSAT exceeds 50% 8, 10
• Occult GI bleeding should be evaluated in non-dialysis CKD patients with iron deficiency, especially in elderly patients 8

When to Consider ESA Therapy

• The National Kidney Foundation recommends considering ESA therapy if hemoglobin remains low despite achieving target iron parameters, but always optimizing iron status first, as 59.4% of patients respond to iron alone 8

Intravenous Iron Therapy for Elderly Non‑Dialysis CKD Patients with Iron‑Deficiency Anemia

Loading Phase

• Iron sucrose 100–125 mg should be administered intravenously for 8–10 consecutive doses (up to three times weekly if outpatient infusion is feasible) to rapidly replete iron stores in elderly non‑dialysis CKD patients with absolute iron deficiency. 11
• Laboratory iron studies (serum ferritin and transferrin saturation) must not be re‑checked until at least 7 days after the final loading dose, because earlier measurements are falsely elevated by recent infusion. 11

Target Iron Parameters

• Aim for minimum targets of TSAT ≥ 20 % and ferritin ≥ 100 ng/mL; optimal hemoglobin response is associated with TSAT ≥ 30 % and ferritin 200–500 ng/mL. (derived from the same loading‑phase protocol) 11
• Discontinue IV iron immediately if ferritin rises above 500–800 ng/mL or TSAT exceeds 50 %, as further supplementation provides little benefit and may increase safety concerns. 11

Maintenance Phase

• After achieving target iron parameters, maintain iron status with 25–125 mg of iron sucrose administered weekly to every two weeks, delivering a total of 250–1,000 mg iron over any 12‑week interval. 11
• TSAT and ferritin should be monitored every 3 months to guide adjustments in maintenance dosing. 11

Clinical Monitoring

• Hemoglobin should be measured 2–4 weeks after completion of the loading course to assess response. 11
• Re‑assessment of ferritin and TSAT should be delayed at least 7 days (preferably 4 weeks) after any IV iron infusion to avoid falsely elevated values. 11

Safety Considerations

• IV iron should be withheld in patients with active infections, because trial participants excluded such patients and iron could theoretically exacerbate infection risk. 12
• If hemoglobin remains <10 g/dL despite achieving iron targets (TSAT ≥ 20 %, ferritin ≥ 100 ng/mL), consider adding erythropoiesis‑stimulating agents, but only after optimal iron repletion. (clinical context) 11

Ongoing Management in the Presence of Hematuria

• Elderly CKD patients with ongoing hematuria (e.g., from a large kidney stone) will likely require continued maintenance IV iron until the bleeding source is definitively treated. 11

All recommendations are based on evidence from the American Journal of Kidney Diseases (2001) and Kidney International (2021).